Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients
Authors
Keywords
-
Journal
ESMO Open
Volume 7, Issue 1, Pages 100337
Publisher
Elsevier BV
Online
2022-02-02
DOI
10.1016/j.esmoop.2021.100337
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC
- (2021) Shannon S. Zhang et al. LUNG CANCER
- Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
- (2020) Tung Hoang et al. Cancers
- TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study
- (2020) T. Mok et al. ANNALS OF ONCOLOGY
- Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
- (2020) Kang Qin et al. BMC CANCER
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
- (2020) Steffen Dietz et al. EBioMedicine
- Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
- (2020) Fabrizio Tabbò et al. Translational Lung Cancer Research
- ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
- (2019) Gina Rosas et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
- (2019) Ibiayi Dagogo-Jack et al. CLINICAL CANCER RESEARCH
- Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
- (2019) Mi Ran Yun et al. EMBO Molecular Medicine
- A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
- (2019) Geeta G. Sharma et al. Journal of Thoracic Oncology
- Clinical Utility of Cell-Free DNA for the Detection ofALKFusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2018) Caroline E. McCoach et al. CLINICAL CANCER RESEARCH
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer
- (2018) Petros Christopoulos et al. INTERNATIONAL JOURNAL OF CANCER
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
- (2018) Jessica J. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
- (2018) Leila Dardaei et al. NATURE MEDICINE
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
- (2018) Satoshi Yoda et al. Cancer Discovery
- Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma
- (2018) P. Christopoulos et al. INTERNATIONAL JOURNAL OF CANCER
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
- (2018) Karim Rihawi et al. Translational Oncology
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types
- (2017) Yongqian Shu et al. Scientific Reports
- Indel variant analysis of short-read sequencing data with Scalpel
- (2016) Han Fang et al. Nature Protocols
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Trimmomatic: a flexible trimmer for Illumina sequence data
- (2014) Anthony M. Bolger et al. BIOINFORMATICS
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started